1,916 material Form 8-K filings that 1,609 companies we cover made with the SEC in July 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Humacyte received a Nasdaq notice that its common stock closed below the $1.00 minimum bid price for 30 consecutive business days ended July 30, 2026. The company has 180 calendar days, until January 27, 2027, to regain compliance, which requires a closing bid of $1.00 or more for at least 10 consecutive business days. Nasdaq says the notice has no immediate effect on the stock's listing, but the company cannot assure it will regain compliance.
Notice received July 31, 2026, for 30 consecutive business days ended July 30, 2026 below $1.00 bid price
Compliance period runs until January 27, 2027 (180 calendar days)
Regaining compliance requires closing bid of $1.00 or more for at least 10 consecutive business days
Stock continues to trade on The Nasdaq Global Select Market under HUMA
A Seoul court ruled against Franklin Technology, a South Korean subsidiary of Franklin Wireless, in a commercial contract dispute with Partron Co. The company is reviewing the decision and evaluating options, including an appeal, and says it intends to vigorously defend its position.
Court ruling issued July 28, 2026 by the Seoul Central District Court (62nd Civil Division)
Damages of approximately $3,673,336 plus 5% annual interest from November 4, 2022 through July 16, 2026
Post-judgment interest of 12% per annum applies from July 17, 2026 until full payment
The dispute relates to a commercial contract for development and production of devices
Traws Pharma received a Nasdaq notice on July 29, 2026 that its common stock has traded below $1.00 per share for at least 30 consecutive business days, so it is not currently meeting the minimum bid price requirement. The notice has no immediate effect on the listing, but the company has until January 25, 2027 to regain compliance, and it could face delisting if it does not.
Nasdaq notice received July 29, 2026 under Listing Rule 5550(a)(2)
Closing bid price was below $1.00 for at least 30 consecutive business days
Compliance period runs until January 25, 2027; regaining compliance requires at least 10 consecutive business days at or above $1.00
A second 180-day grace period may be available if the company meets listing standards and gives notice of intent to cure
GD Culture Group received written notice from Nasdaq on July 29, 2026 that it has regained compliance with the $1.00 minimum bid price requirement for continued listing on The Nasdaq Capital Market, and that the matter is now closed. The notice removes the bid price deficiency as an open listing issue for the company's shares.
Nasdaq notice dated July 29, 2026 confirms regained compliance with the $1.00 minimum bid price requirement
Compliance is under Nasdaq Listing Rule 5550(a)(2); Nasdaq states the matter is now closed
Filing also incorporates this report into the company's Form S-3 registration statement (File No. 333-292934)
Context Therapeutics received a Nasdaq notice on July 29, 2026 stating its common stock failed to maintain a $1.00 minimum closing bid price for 30 consecutive business days. The company has until January 25, 2027 to regain compliance, and the notice has no immediate effect on its listing or trading, but failure to regain compliance could lead to delisting proceedings.
Nasdaq notice dated July 29, 2026 cites Listing Rule 5550(a)(2), the minimum bid price rule
Compliance deadline is January 25, 2027, after a 180 calendar day initial period
Company may be eligible for an additional 180-day Second Compliance Period if it meets listing requirements and notifies Nasdaq of its intent to cure
The notice has no immediate effect on the company's listing or trading
DocGo received a Nasdaq letter on July 28, 2026, granting an additional 180 calendar days, until January 25, 2027, to regain compliance with the minimum bid price requirement. The company's stock must close at or above $1.00 for at least 10 consecutive business days to regain compliance, and the company says it cannot assure it will do so in time. Shareholders should note that the company may pursue a reverse stock split, which stockholders approved at the June 16, 2026 annual meeting.
Nasdaq granted an additional 180 calendar days, until January 25, 2027, to meet the $1.00 minimum bid price requirement
Compliance requires a closing bid price of at least $1.00 for a minimum of 10 consecutive business days
Stockholders approved a reverse stock split at ratios of 1-for-5 to 1-for-10 at the June 16, 2026 annual meeting, with the final ratio to be set by the Board
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.